Back to Search Start Over

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Authors :
Riko Ikeda
Yoh Matsuoka
Masaharu Inoue
Ayataka Ishikawa
Kiwamu Akagi
Yukio Kageyama
Source :
IJU Case Reports, Vol 7, Iss 2, Pp 115-119 (2024)
Publication Year :
2024
Publisher :
Wiley, 2024.

Abstract

Introduction The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially diagnosed with prostate adenocarcinoma developed treatment‐related neuroendocrine prostate cancer after 10‐year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects. Conclusion Olaparib may be the treatment of choice for treatment‐related neuroendocrine prostate cancer in patients with BRCA mutations.

Details

Language :
English
ISSN :
2577171X
Volume :
7
Issue :
2
Database :
Directory of Open Access Journals
Journal :
IJU Case Reports
Publication Type :
Academic Journal
Accession number :
edsdoj.822a7eb106a34c9a8305a49dc6c19ff2
Document Type :
article
Full Text :
https://doi.org/10.1002/iju5.12679